Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the most promising stocks on our list.

TheFly reported on June 12 that Guggenheim analyst Brad Canino reduced the price target for SNDX to $31 from $34 while maintaining a Buy rating on the shares. The updated outlook reflected revisions to the firm’s acute myeloid leukemia market assumptions following new insights on revumenib’s post-transplant maintenance duration from recent medical conference updates. The analyst also considered recent commercial updates from Syndax and Kura Oncology when adjusting the valuation.

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?

Moreover, on June 11, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced the publication of clinical results from the Phase 1/2 SAVE trial evaluating an oral combination regimen of Revuforj (revumenib), decitabine/cedazuridine, and venetoclax in patients with relapsed or refractory acute myeloid leukemia with NPM1 mutations, KMT2A rearrangements, or NUP98 rearrangements. The data were published in the Journal of Clinical Oncology and presented at the 2026 European Hematology Association Congress. The study enrolled 42 patients, including adolescents, and showed an overall response rate of 88% with a 71% composite complete remission rate. The regimen demonstrated activity across genetic subgroups, including patients previously treated with venetoclax, while maintaining a generally manageable safety profile.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a commercial-stage biopharmaceutical company developing innovative therapies for cancer and immune-mediated diseases, with a focus on hematologic malignancies.

While we acknowledge the risk and potential of SNDX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SNDX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1